Description
Key facts
Cell type:A-431,
Species or organism:Human,
Tissue:Skin,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 2 bp deletion Frameshift: 100%,
Disease:Epidermoid Carcinoma
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-BCAM, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions--196°C, -80°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD239 also known as basal cell adhesion molecule (BCAM) is an integral protein with a mass of about 60 kDa. This protein is primarily expressed in endothelial cells red blood cells and various epithelial tissues. BCAM plays a significant role in cell adhesion acting as a receptor for the extracellular matrix component laminin specifically laminin-511/521. It helps cells attach an essential role for maintaining tissue integrity and cellular communication.
Biological function summary
BCAM influences processes related to cell adhesion and motility. Although not explicitly part of a large complex it interacts closely with the cytoskeleton and mediators of signal transduction. Functions of BCAM involve linking extracellular matrix signals to the intracellular environment impacting cell movement and stabilization within tissues. It also modulates cellular responses to external mechanical stresses playing essential roles in maintaining normal cell function.
Pathways
BCAM is involved in several critical signaling processes including integrin-mediated adhesion and the MAPK/ERK pathway. How BCAM affects these pathways is through its interaction with integrins and elements related to cellular migration and proliferation. Within these pathways related proteins like laminins and other integrin subunits contribute to its adhesion properties and signaling functions enabling coordinated cellular responses to environmental cues.
BCAM is notably associated with sickle cell disease and certain cancers. In sickle cell disease the altered expression or function of BCAM on red blood cells causes abnormal adhesion to the endothelium leading to vaso-occlusion. This adhesion is often exacerbated by interactions with other proteins like L-selectin. In cancer BCAM overexpression correlates with increased tumor cell migration and invasion influencing metastasis and patient prognosis. These associations highlight BCAM's critical role in disease pathology and potential as a therapeutic target.
